ASCL1 and glioblastoma: Therefore, this data suggests that the treatments that activate MASH1 may be useful in anti-GBM therapy as the simulation outcomes depicted the possible suppression mechanisms of both LGG-I and Grade-IV tumor cells in the simulated therapeutic conditions.